Your browser is no longer supported. Please, upgrade your browser.
AMRN Amarin Corporation plc daily Stock Chart
AMRN [NASD]
Amarin Corporation plc
Index- P/E- EPS (ttm)-0.25 Insider Own0.60% Shs Outstand294.42M Perf Week-5.59%
Market Cap945.09M Forward P/E- EPS next Y-0.03 Insider Trans0.00% Shs Float149.51M Perf Month-1.83%
Income-68.60M PEG- EPS next Q-0.09 Inst Own42.90% Short Float2.74% Perf Quarter0.31%
Sales190.40M P/S4.96 EPS this Y40.70% Inst Trans11.27% Short Ratio2.01 Perf Half Y-5.31%
Book/sh-0.14 P/B- EPS next Y91.40% ROA-39.80% Target Price7.60 Perf Year7.00%
Cash/sh0.44 P/C7.33 EPS next 5Y20.40% ROE107.60% 52W Range2.66 - 4.60 Perf YTD-19.95%
Dividend- P/FCF- EPS past 5Y27.90% ROI-169.80% 52W High-29.57% Beta0.69
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin75.10% 52W Low21.66% ATR0.13
Employees241 Current Ratio1.70 Sales Q/Q26.90% Oper. Margin-25.70% RSI (14)51.29 Volatility4.28% 4.36%
OptionableYes Debt/Eq- EPS Q/Q-9.00% Profit Margin-37.30% Rel Volume0.64 Prev Close3.21
ShortableYes LT Debt/Eq- EarningsMay 02 BMO Payout- Avg Volume2.03M Price3.24
Recom1.60 SMA20-1.13% SMA503.40% SMA200-5.27% Volume256,758 Change0.93%
Jun-27-17Resumed Cantor Fitzgerald Overweight
Oct-19-16Initiated Citigroup Buy $5
Oct-05-16Initiated Cantor Fitzgerald Buy $6
May-12-16Resumed Jefferies Buy
Mar-12-15Upgrade H.C. Wainwright Neutral → Buy $2.50 → $10
Apr-01-14Reiterated MKM Partners Neutral $1.50 → $2
Feb-24-14Reiterated MKM Partners Neutral $2.50 → $1.75
Jan-16-14Downgrade MKM Partners Buy → Neutral $2.50
Nov-08-13Reiterated MKM Partners Buy $5 → $2.50
Oct-30-13Initiated FBR Capital Mkt Perform $2
Oct-17-13Reiterated MKM Partners Buy $9 → $5
Oct-17-13Downgrade Canaccord Genuity Buy → Hold $10 → $3
Oct-17-13Downgrade Aegis Capital Buy → Hold
Mar-20-13Initiated Chardan Capital Markets Hold $8.50
Dec-10-12Reiterated Aegis Capital Buy $25 → $35
Dec-07-12Reiterated Aegis Capital Buy $25 → $35
Jul-12-11Initiated MKM Partners Buy $23
Apr-25-11Reiterated Wedbush Outperform $12 → $18
Apr-18-11Reiterated Canaccord Genuity Buy $11 → $18
Dec-29-10Reiterated Wedbush Outperform $7 → $10
Jun-12-18 05:00AM  Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications GlobeNewswire
Jun-07-18 05:00AM  Amarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions GlobeNewswire
Jun-06-18 07:40AM  Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jun-04-18 07:30AM  Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks ACCESSWIRE
May-25-18 09:19AM  Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended Benzinga
May-24-18 04:35PM  Amarin Announces Patent Litigation Settlement Agreement with Teva GlobeNewswire
May-23-18 04:30PM  Amarin to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-21-18 08:48AM  Is the Options Market Predicting a Spike in Amarin (AMRN) Stock? Zacks -5.20%
May-09-18 04:05AM  Edited Transcript of AMRN earnings conference call or presentation 2-May-18 11:30am GMT Thomson Reuters StreetEvents
May-02-18 05:52AM  Amarin: 1Q Earnings Snapshot Associated Press
05:00AM  Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations GlobeNewswire
May-01-18 06:02AM  3 Stocks That Could Put Tesla's Returns to Shame Motley Fool
Apr-26-18 05:00AM  Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018 GlobeNewswire +6.72%
Apr-24-18 08:45AM  Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock? Zacks
Apr-23-18 05:00AM  Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer GlobeNewswire
Apr-13-18 08:20AM  New Research: Key Drivers of Growth for Amarin, Korea Electric Power, Star Bulk Carriers, 1-800 FLOWERS.COM, Clementia Pharmaceuticals, and Bank of Nova Scotia Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Apr-12-18 04:30PM  Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions GlobeNewswire
10:22AM  Moving Average Crossover Alert: Amarin (AMRN) Zacks
05:00AM  Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides GlobeNewswire
Apr-06-18 07:30AM  Wired News Amarins REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACE ACCESSWIRE
Apr-04-18 07:16PM  Boom-or-Bust News Is On Tap Soon for Amarin Motley Fool +7.85%
05:15AM  Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives GlobeNewswire
05:00AM  Amarins REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events GlobeNewswire
Apr-02-18 08:46AM  Implied Volatility Surging for Amarin (AMRN) Stock Options Zacks
06:00AM  7 Stocks for the Biotech Takeover Wave Investopedia
Mar-31-18 03:25AM  Edited Transcript of AMRN earnings conference call or presentation 27-Feb-18 12:30pm GMT Thomson Reuters StreetEvents
Mar-29-18 05:00AM  Amarin Sponsors Two Scientific Presentations Scheduled for National Kidney Foundation 2018 Spring Clinical Meetings GlobeNewswire
Mar-28-18 04:30PM  Amarin to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-27-18 04:30PM  Amarin Commemorates National Triglycerides Day on March 28 GlobeNewswire
Mar-21-18 05:00AM  Amarin Announces First Middle East Approval for Vascepa® GlobeNewswire
Mar-20-18 08:46AM  3 Stocks That Could Put Alibaba's Returns to Shame Motley Fool
Mar-16-18 08:10AM  New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-12-18 04:30PM  Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP) GlobeNewswire
04:30PM  Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs GlobeNewswire
Mar-09-18 07:18PM  Cramer's lightning round: I screwed up on Apache and won'... CNBC Videos
06:51PM  Cramer's lightning round: I screwed up on Apache and won't stop you from selling CNBC
Mar-05-18 04:35PM  Amarin Announces Closing of Underwriters Purchase of Additional Shares GlobeNewswire
08:50AM  Implied Volatility Surging for Amarin (AMRN) Stock Options Zacks
Mar-01-18 05:00AM  Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study GlobeNewswire
Feb-28-18 05:00AM  Amarin Sponsors Multiple Scientific Presentations Scheduled for 2018 American College of Cardiology Annual Scientific Session & Expo GlobeNewswire
Feb-27-18 05:41AM  Amarin reports 4Q loss Associated Press
05:00AM  Amarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations GlobeNewswire
Feb-20-18 04:30PM  Amarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018 GlobeNewswire
Jan-30-18 08:58AM  Amarin Prices Public Offering of American Depositary Shares GlobeNewswire
Jan-29-18 04:21PM  Amarin Corporation plc (ADR) (AMRN) Cashes Out; Shares Tumble SmarterAnalyst -6.09%
04:01PM  Amarin Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Jan-24-18 09:09AM  Heres Whats Moving Amarin Corporation and Puma Biotechnology Market Exclusive
08:51AM  Amarin (AMRN) Soars: Stock Adds 9.9% in Session Zacks
Jan-23-18 12:13PM  Why Amarin Corporation Stock Is Surging Today Motley Fool +9.90%
06:00AM  Amarins REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events GlobeNewswire
Jan-19-18 07:20AM  Wired News Amarin Initiates Clinical Development of VASCEPA in Mainland China ACCESSWIRE
Jan-17-18 06:00AM  Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China GlobeNewswire
Jan-04-18 05:32PM  Company Update (NASDAQ:AMRN): Amarin Corporation plc Provides Preliminary 2017 Results and Provides 2018 Outlook SmarterAnalyst
04:30PM  Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook GlobeNewswire
Dec-21-17 08:58AM  Amarin Corporation (AMRN) in Focus: Stock Moves 8.9% Higher Zacks
Dec-19-17 12:15PM  ETFs with exposure to Amarin Corp. Plc : December 19, 2017 Capital Cube
06:00AM  Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018 GlobeNewswire
Dec-18-17 04:30PM  Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco GlobeNewswire
10:00AM  3 Growth Stocks to Own in 2018 Motley Fool
Nov-28-17 11:47AM  ETFs with exposure to Amarin Corp. Plc : November 28, 2017 Capital Cube
Nov-14-17 04:30PM  Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk GlobeNewswire
Nov-13-17 04:30PM  Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease GlobeNewswire
06:00AM  Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical Costs GlobeNewswire
Nov-07-17 07:00AM  Corporate News Blog - Ionis Submits Marketing Authorization Application to EMA for Inotersen ACCESSWIRE
06:00AM  Amarin to Present at the Jefferies London Healthcare Conference GlobeNewswire
Nov-06-17 11:03AM  ETFs with exposure to Amarin Corp. Plc : November 6, 2017 Capital Cube
Nov-03-17 09:58AM  Amarin Corp. Plc :AMRN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
Nov-01-17 06:16PM  Edited Transcript of AMRN earnings conference call or presentation 1-Nov-17 12:00pm GMT Thomson Reuters StreetEvents
08:43AM  Company Update (NASDAQ:AMRN): Amarin Corporation plc (ADR) Announces 3Q:17 Financial Results and Provides Update on Operations SmarterAnalyst
06:29AM  Amarin reports 3Q loss Associated Press
05:30AM  Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations GlobeNewswire
Oct-25-17 06:00AM  Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017 GlobeNewswire
Oct-23-17 10:19AM  ETFs with exposure to Amarin Corp. Plc : October 23, 2017 Capital Cube
Oct-19-17 07:30AM  3 Small-Cap Biotech Stocks That Could Be Big Winners in 2018 Motley Fool
Oct-10-17 10:58AM  ETFs with exposure to Amarin Corp. Plc : October 10, 2017 Capital Cube
Sep-28-17 10:09AM  ETFs with exposure to Amarin Corp. Plc : September 28, 2017 Capital Cube
Sep-25-17 06:00AM  Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in Canada GlobeNewswire
Sep-20-17 04:30PM  Amarin to Present at Cantor Global Healthcare Conference GlobeNewswire
Sep-13-17 06:00AM  Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer GlobeNewswire
Sep-11-17 08:20PM  ETFs with exposure to Amarin Corp. Plc : September 12, 2017 Capital Cube
Sep-06-17 06:00AM  Amarin to Present at Rodman & Renshaws Global Investment Conference GlobeNewswire
Aug-31-17 05:12PM  ETFs with exposure to Amarin Corp. Plc : August 31, 2017 Capital Cube
Aug-25-17 10:45AM  Amarin Corp. Plc :AMRN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Aug-14-17 07:10AM  Featured Company News GlaxoSmithKline Drops Options to Licence Inotersen and IONIS-FB-LRx; Ionis Pharma to Continue Development Independently ACCESSWIRE
06:00AM  Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee GlobeNewswire
Aug-12-17 01:15AM  Edited Transcript of AMRN earnings conference call or presentation 2-Aug-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-04-17 08:58AM  Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock? Zacks
Aug-02-17 10:55PM  Amarin reports 2Q loss Associated Press
12:32PM  Here's Why Amarin Corporation plc Is on the Rise Today Motley Fool
06:00AM  Investor Network: Amarin Corporation Plc to Host Earnings Call ACCESSWIRE
05:30AM  Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations GlobeNewswire
Aug-01-17 04:05PM  Investor Calendar Invites You to the Amarin Second Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, August 2, 2017 ACCESSWIRE
Jul-26-17 04:30PM  Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017 GlobeNewswire
Jul-10-17 01:29PM  Here's Why Amarin Corporation plc Surged 34% Higher in June Motley Fool
Jun-28-17 08:42AM  Is the Options Market Predicting a Spike in Amarin (AMRN) Stock? Zacks +8.31%
08:00AM  Today's Research Reports on Stocks to Watch: OraSure Technologies and Amarin Corporation Accesswire
Jun-27-17 02:51PM  ETFs with exposure to Amarin Corp. Plc : June 27, 2017 Capital Cube
Jun-26-17 05:01PM  Cantor Pounds The Table On Amarin Corporation plc (ADR) (AMRN) SmarterAnalyst
01:08PM  3 Cheap Healthcare Stocks You Can Buy Right Now Motley Fool
Jun-13-17 09:29AM  Opening Bell, June 13, 2017 CNBC Videos
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers through direct sales force. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.